Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study
- 10 July 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (2), 402-404
- https://doi.org/10.1038/leu.2008.185
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic VariantsThe Journal of pharmacology and experimental therapeutics, 2007
- CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyBlood, 2007
- Pharmacokinetics of Gemtuzumab Ozogamicin as a Single‐Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid LeukemiaThe Journal of Clinical Pharmacology, 2004
- Clinical significance of residual disease during treatment in childhood acute myeloid leukaemiaBritish Journal of Haematology, 2003
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001
- Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapseExpert Opinion on Biological Therapy, 2001
- Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.2001
- The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score.2000
- The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic scoreBlood, 2000
- Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove.Proceedings of the National Academy of Sciences of the United States of America, 1995